Capitainer Secures SEK 21 million to Boost Production and Establish Its Presence on the American Market
Swedish medtech company Capitainer secures about SEK 21 million in funding to boost its production capabilities and broaden its sales efforts across Europe and the U.S. The investment, led by Sciety and the Sciety Venture Partners network, underscores the strong confidence and growing interest in Capitainer's breakthrough technology and potential to advance the healthcare sector.
Capitainer offers an innovative self-sampling platform for fingertip blood collection, designed to streamline and enhance the accuracy of the collection process—critical for ensuring dependable test results. By facilitating easy home-based sampling, Capitainer is reducing barriers to regular health monitoring. This improved access and simplicity in managing one's own health are set to significantly enhance the quality of life for people globally.
Capitainer aims to establish itself as the leading provider of self-sampling solutions. Leveraging the recent capital injection, Capitainer is set to expand its production lines and strengthen its sales force in both Europe and the American market to achieve its strategic objectives. The company will also continue to enhance its collaborations with global partners and focus on implementing its products in clinical settings to boost sales and intensify marketing efforts.
"This strategic capital boost allows us to fast-track our expansion, with a particular focus on enhancing our presence in the USA, where we recently inaugurated our own laboratory. We are actively engaging in major sales initiatives in several countries across Europe and the USA. The steadfast support from our shareholders and Sciety significantly drives and accelerates our ongoing growth," states Christopher Aulin, CEO of Capitainer.
Sciety and the Sciety Venture Partners network invest in Capitainer for the fourth time since 2020.
"We are enthusiastic about continuing our investment in Capitainer and supporting their mission to revolutionize blood sampling. The innovative platform by Capitainer stands at the forefront of advancing personalized medicine and remote healthcare, closely aligning with Sciety's vision that scientific breakthroughs in medicine and technology should be accessible worldwide," says Andreas Lindblom, Managing Partner at Sciety.
For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Email: christopher.aulin@capitainer.com
About Capitainer
Capitainer AB is a Swedish MedTech company that develops and sells patient-centric solutions for self-sampling of blood, plasma, and urine. Founded in 2016, Capitainer has developed unique technologies for collecting and drying exact volumes of fluid within easy-to-use sampling cards. These cards may be sent as standard post to relevant testing laboratories, thus bypassing the need for cold chain logistics and specialised packaging. Capitainer’s products are market-leading with respect to precision and accuracy, with demonstrated equal performance to established pipetting methods. The products are applicable within several market segments, including but not limited to, clinical biomarkers, therapeutic drug monitoring, genomics, drug abuse and doping testing, and R&D and clinical studies.
About Sciety
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world. For more information, please visit www.sciety.com and follow us on LinkedIn.
Tags:
